DAVID FRANKEL: Open Payments
NPI 1811052574 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,250 in 64 payments from 13 companies in 2025. Trend: 2023 $1,542 · 2024 $1,474 · 2025 $1,250
Food & beverage: $1,250
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 14 | $313 |
| Alkermes, Inc. | 11 | $160 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $153 |
| Teva Pharmaceuticals USA, Inc. | 9 | $138 |
| Neurocrine BioSciences, Inc. | 5 | $115 |
| Otsuka America Pharmaceutical, Inc. | 4 | $95 |
| E.R. Squibb & Sons, L.L.C. | 4 | $93 |
| Almatica Pharma LLC | 2 | $45 |
| ABBVIE INC. | 2 | $35 |
| Corium, LLC | 1 | $31 |
Products named: FANAPT, CAPLYTA, AUSTEDO XR, ARISTADA, INGREZZA, COBENFY, ABILIFY ASIMTUFII, LOREEV XR.
Industry payments across PA — which companies pay providers there.
